The highest overall response rate (ORR) was observed in patients treated with the lowest dose of axatilimab at 0.3 mg/kg every 2 weeks, with an ORR of 74% (95% CI 63-83) within the first 6 months, ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Primary end point was met, with overall response for 74, 67, and 50% receiving axatilimab 0.3-, 1-, and 3mg per kilogram of body weigh HealthDay News — For patients with recurrent or refractory ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

Please provide your email address to receive an email when new articles are posted on . Lirentelimab improved disease control among patients with antihistamine-refractory chronic urticaria, according ...

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...

Less than half of the healthcare providers correctly identified refractory chronic cough (RCC) as a cough lasting more than 8 weeks and not responding to treatment, based on survey data from more than ...

Chronic cough, defined as a cough lasting at least 8 weeks, affects approximately 5% of the European population, particularly older adults and individuals with a history of smoking. In some cases, ...

Feasibility of 6 months of maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck (HNC). This is an ASCO Meeting Abstract from ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today provided a corporate update, including an update on the encouraging enrollment ...

Introduction Refractory headache is a common and frequently disabling disorder, affecting 2–12 million patients each year in ...